Control of porphyria cutanea tarda with anti-IL-17 secukinumab in a person with psoriasis living with HIV.
Journal
Oxford medical case reports
ISSN: 2053-8855
Titre abrégé: Oxf Med Case Reports
Pays: England
ID NLM: 101642070
Informations de publication
Date de publication:
Jul 2023
Jul 2023
Historique:
received:
03
02
2023
revised:
13
04
2023
accepted:
29
05
2023
medline:
24
7
2023
pubmed:
24
7
2023
entrez:
24
7
2023
Statut:
epublish
Résumé
A 65-year-old woman successfully treated for human immunodeficiency virus (HIV) and Hepatitis C virus was diagnosed with porphyria cutanea tarda (PCT) and treated by phlebotomies. She developed extensive psoriatic skin lesions resistant to topical treatments and methotrexate. She then received the anti-interleukin-17 (IL-17) secukinumab (Cosentyx) which improved her psoriatic skin lesions. Unexpectedly, her PCT skin lesions healed, allowing phlebotomy discontinuation over 2 years. Without lesions, the patient decided to discontinue secukinumab, leading to the recurrence of psoriatic and PCT skin lesions, which were controlled upon therapeutical rechallenge. No AIDS-related manifestations or infections developed, her CD4 count remained elevated and her HIV viral load was controlled under antiretroviral therapy. Both skin conditions and consequently the patient's quality of life have improved with secukinumab, allowing exposure to sunlight and phlebotomy discontinuation for >4 years. Likely, the IL-17 pathway is involved in the clinical manifestations of PCT, opening new avenues for therapeutical interventions.
Identifiants
pubmed: 37484558
doi: 10.1093/omcr/omad066
pii: omad066
pmc: PMC10359061
doi:
Types de publication
Case Reports
Langues
eng
Pagination
omad066Informations de copyright
© The Author(s) 2023. Published by Oxford University Press. All rights reserved. For Permissions, please email: journals.permissions@oup.com.
Déclaration de conflit d'intérêts
None declared.
Références
N Engl J Med. 2017 Aug 31;377(9):862-872
pubmed: 28854095
Lancet. 2007 Jul 21;370(9583):263-271
pubmed: 17658397
Metabolites. 2022 Aug 31;12(9):
pubmed: 36144223
Gastroenterology. 2019 Aug;157(2):365-381.e4
pubmed: 31085196
Am Health Drug Benefits. 2016 Mar;9(Spec Feature):60-3
pubmed: 27668046
Pharmaceuticals (Basel). 2022 Nov 07;15(11):
pubmed: 36355537
Nat Rev Immunol. 2023 Jan;23(1):38-54
pubmed: 35790881
Clin Exp Immunol. 2017 Mar;187(3):466-479
pubmed: 27859020